A Phase 1 interventional study of Semaglutide in Healthy Participants, sponsored by Novo Nordisk A/S. Completed at 1 site in Canada. Open to male participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
In this study, a known medicine called 'semaglutide' will be tested in two different tablet versions. The two tablets differ in the way these have been manufactured. The aim of the study is to investigate the amount of active ingredient in the blood after dosing the different tablet versions. Participants will receive one tablet version for 10 days (first treatment period) and the other version for 10 days (second treatment period). The treatment arm participants will be assigned to is decided by chance. The study will last for about 23 weeks for each participant. The study will enroll healthy male participants.
Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 102 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key inclusion criteria:
Key exclusion criteria:
Oral semaglutide J will be administered in treatment period 1 followed by semaglutide K in treatment period 2.
Drug: Semaglutide
Oral semaglutide K will be administered in treatment period 1 followed by semaglutide J in treatment period 2.
Drug: Semaglutide
Oral administration
Adjusted AUC0-24h,sema; adjusted area under the semaglutide plasma concentration-time curve
Measured in hour\*nanomoles per liter (h\*nmol/L).
Time frame: From 0 to 24 hours after dosing on day 80 and 90
Adjusted Cmax,0-24h,sema; adjusted maximum observed semaglutide plasma concentration
Measured in nanomoles per liter (nmol/L).
Time frame: From 0 to 24 hours after dosing on day 80 and 90
Adjusted tmax,0-24h,sema; time to adjusted maximum observed semaglutide plasma concentration
Measured in hours.
Time frame: From 0 to 24 hours after dosing on day 80 and 90
t½,sema; the terminal half-life of semaglutide
Measured in hours.
Time frame: From 0 to 840 hours after dosing on day 90
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S